{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-26-002705","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2026-05-14T20:11:39+00:00","discovered_at":"2026-05-14T20:13:01.306886+00:00","generated_at":"2026-05-14T20:54:38.020359+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silexion reports positive preclinical SIL204 data showing increased MHC-I in KRAS-mutated pancreatic cancer","bullets":["SIL204 significantly increased MHC-I (HLA-ABC) surface expression in human KRAS G12R pancreatic cancer cells at 60 nM (p<0.05).","Increased MHC-I may enhance T cell recognition, supporting potential combination with anti-PD-1 therapies like Keytruda.","CEO Ilan Hadar said SIL204 may influence immune evasion pathways in addition to direct anti-tumor activity.","Pancreatic cancer is immunologically resistant; MHC-I loss is a key immune evasion mechanism in KRAS-driven tumors."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-26-002705","json":"https://secwatch.observer/filing/0001178913-26-002705.json","markdown":"https://secwatch.observer/filing/0001178913-26-002705.md","text":"https://secwatch.observer/filing/0001178913-26-002705.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002705/0001178913-26-002705-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891326002705/zk2635307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T20:54:38.020359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}